Delcath Systems Inc
Company Profile
Business description
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Contact
566 Queensbury Avenue
QueensburyNY12804
USAT: +1 518 743-8892
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
156
Stocks News & Analysis
stocks
Shares leap for ASX rare earths provider
stocks
Does SpaceX’s sky-high valuation make sense?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,851.40 | 29.00 | -0.33% |
| CAC 40 | 8,021.70 | 20.11 | -0.25% |
| DAX 40 | 23,629.42 | 10.61 | -0.04% |
| Dow JONES (US) | 47,417.27 | 289.24 | -0.61% |
| FTSE 100 | 10,328.61 | 25.16 | -0.24% |
| HKSE | 25,716.76 | 182.00 | -0.70% |
| NASDAQ | 22,716.13 | 19.03 | 0.08% |
| Nikkei 225 | 54,452.96 | 572.41 | -1.04% |
| NZX 50 Index | 13,199.29 | 104.92 | 0.80% |
| S&P 500 | 6,775.80 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,629.00 | 14.20 | -0.16% |
| SSE Composite Index | 4,129.10 | 4.33 | -0.10% |